The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers
Doggrell, Sheila Anne (2010) The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers. Expert Opinion on Investigational Drugs, 19(3), pp. 451-454.
Background: The hedgehog signaling pathway is vital in early development, but then becomes dormant, except in some cancer tumours. Hedgehog inhibitors are being developed for potential use in cancer. Objectives/Methods: The objective of this evaluation is to review the initial clinical studies of the hedgehog inhibitor, GDC-0449, in subjects with cancer. Results: Phase I trials have shown that GDC-0449 has benefits in subjects with metastatic or locally advanced basal-cell carcinoma and in one subjects with medulloblastoma. GDC-0449 was well tolerated. Conclusions: Long term efficacy and safety studies of GDC-0449 in these conditions and other solid cancers are now underway. These clinical trials with GDC-0449, and trials with other hedgehog inhibitors, will reveal whether it is beneficial and safe to inhibit the hedgehog pathway, in a wide range of solid tumours or not.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||basal-cell carcinoma, , GDC-0449, , hedgehog inhibitors, , medulloblastoma|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Basic Pharmacology (111501)|
|Divisions:||Past > QUT Faculties & Divisions > Faculty of Science and Technology
Past > Schools > Medical Sciences
|Copyright Owner:||Copyright 2010 Informa UK Ltd|
|Deposited On:||03 Nov 2010 01:51|
|Last Modified:||25 Mar 2015 02:58|
Repository Staff Only: item control page